Cargando…

CYP2C19*2 Polymorphism Is Associated with Impaired Oral Clearance of Gliclazide in Healthy Chinese

BACKGROUND: Previous studies suggest gliclazide is metabolised primarily by CYP2C19 rather than CYP2C9, unlike other sulphonylureas. CYP2C19 *2 and *3 polymorphisms are more common in Asians. METHODS: We investigated the effect of CYP2C19 polymorphisms on gliclazide pharmacokinetics in 15 healthy ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chow, Elaine, Poon, Emily WM, Fok, Benny SP, Chan, Juliana CN, Tomlinson, Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997415/ https://www.ncbi.nlm.nih.gov/pubmed/32099442 http://dx.doi.org/10.2147/PGPM.S226200

Ejemplares similares

Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype
por: Dujic, Tanja, et al.
Publicado: (2021)

CYP2C9 and OATP1B1 genetic polymorphisms affect the metabolism and transport of glimepiride and gliclazide
por: Yang, Fayou, et al.
Publicado: (2018)

Preparation and Crystallographic Analysis of Gliclazide Polymorphs
por: Rajamma, A. J., et al.
Publicado: (2015)

CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients
por: Zeng, Wotan, et al.
Publicado: (2016)

Bioequivalence Study of Modified-Release Gliclazide Tablets in Healthy Volunteers
por: Rojanasthien, Noppamas, et al.
Publicado: (2012)

CYP1A2 polymorphism and theophylline clearance in Korean non-smoking asthmatics
por: Yim, Eun-Young, et al.
Publicado: (2013)

Fabrication and Characterization of Gliclazide Nanocrystals
por: Ravouru, Nagaraju, et al.
Publicado: (2018)

CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults
por: Muhareb, Amin, et al.
Publicado: (2023)

Factors Associated with Aspirin Resistance in Hong Kong Chinese Patients with Stable Coronary Heart Disease Using the Multiplate(®) Analyzer and Serum Thromboxane B(2)
por: Zeng, Weiwei, et al.
Publicado: (2022)

Pharmacokinetics and Anti-Diabetic Studies of Gliclazide Nanosuspension
por: Sampathi, Sunitha, et al.
Publicado: (2022)

Acute Exfoliative Dermatitis/Erythroderma Secondary to Gliclazide
por: Al-Badawi, Saifaldeen, et al.
Publicado: (2023)

CYP2C19 Loss‐of‐function Polymorphisms are Associated with Reduced Risk of Sulfonylurea Treatment Failure in Chinese Patients with Type 2 Diabetes
por: Wang, Ke, et al.
Publicado: (2021)

Influence of curcumin on the pharmacodynamics and pharmacokinetics of gliclazide in animal models
por: Vatsavai, Leela Krishna, et al.
Publicado: (2016)

Influence of aprepitant on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits
por: Kura, Raghunandan Reddy, et al.
Publicado: (2018)

Bioavailability and Antidiabetic Activity of Gliclazide-Loaded Cubosomal Nanoparticles
por: Nasr, Mohamed, et al.
Publicado: (2021)

Effect of Gliclazide or Gliclazide plus Metformin Combination on Glycemic Control in Patients with T2DM in India: A Real-World, Retrospective, Longitudinal, Observational Study from Electronic Medical Records
por: Polavarapu, Nareen Krishna, et al.
Publicado: (2020)

A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans
por: Ryu, S, et al.
Publicado: (2017)

Influence of CYP2D6 and CYP3A5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients
por: Chan, Sze Wa, et al.
Publicado: (2021)

Effect of CYP4F2 Polymorphisms on Ticagrelor Pharmacokinetics in Healthy Chinese Volunteers
por: Nie, Shanshan, et al.
Publicado: (2022)

The influence of physical division of tablets on the variability of release kinetics of gliclazide
por: Wójcik-Pastuszka, Dorota, et al.
Publicado: (2018)

Interaction of p-synephrine on the pharmacodynamics and pharmacokinetics of gliclazide in animal models
por: Vatsavai, Leela Krishna, et al.
Publicado: (2018)

Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma
por: Cheng, Yang, et al.
Publicado: (2021)

Hypoglycemia with gliclazide MR in women with type 2 diabetes. A continuous glucose monitoring study
por: Vianna, André G Daher, et al.
Publicado: (2015)

The Role of Real-World Evidence in Treatment Decision-Making, Regulatory Assessment, and Understanding the Perspectives of People with Type 2 Diabetes: Examples with Gliclazide MR
por: Khunti, Kamlesh, et al.
Publicado: (2023)

Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats
por: Al-Salami, Hani, et al.
Publicado: (2008)

Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population
por: Kudzi, William, et al.
Publicado: (2009)

Association between TCF7L2 Genotype and Glycemic Control in Diabetic Patients Treated with Gliclazide
por: Javorský, Martin, et al.
Publicado: (2013)

The Effects of Gliclazide, Metformin, and Acarbose on Body Composition in Patients with Newly Diagnosed Type 2 Diabetes Mellitus()
por: Wang, Hua, et al.
Publicado: (2013)

Effects of gliclazide add on metformin on serum omentin-1 levels in patients with type 2 diabetes mellitus
por: Al-Gareeb, Ali I., et al.
Publicado: (2016)

Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial
por: Leiter, Lawrence A., et al.
Publicado: (2018)

Gliclazide: Unmasking of glucose-6-phosphate dehydrogenase deficiency: case report
Publicado: (2021)

Comment on Dawed et al. Genome-Wide Meta-Analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673–2682
por: Wang, Ke, et al.
Publicado: (2022)

CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers
por: Gawrońska-Szklarz, Barbara, et al.
Publicado: (2012)

Influence of CYP2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamic Characteristics of Carvedilol in Healthy Korean Volunteers
por: Jung, Eben, et al.
Publicado: (2018)

Effects of Genetic Polymorphisms of CYP2B6 on the Pharmacokinetics of Bupropion and Hydroxybupropion in Healthy Chinese Subjects
por: Ma, Hui, et al.
Publicado: (2018)

Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
por: Gardin, Anne, et al.
Publicado: (2018)

Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia
por: Giraldo-Ocampo, Sebastian, et al.
Publicado: (2023)

A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children
por: Brussee, Janneke M., et al.
Publicado: (2019)

Safety and Efficacy of Gliclazide as Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Trials
por: Landman, Gijs W. D., et al.
Publicado: (2014)

Gliclazide alone or in combination with atorvastatin ameliorated reproductive damage in streptozotocin-induced type 2 diabetic male rats
por: Öztaş, Ezgi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hapd9dktfl7pgpd2rvpfm90j2e